Dr Reddy's Laboratories. Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 12,22,604 shares,. Its Average Traded Price (ATP) is ₹1380.06, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹1386.60.
Dr Reddy's Laboratories. has an upper circuit limit of ₹1514.70 and a lower circuit limit of ₹1239.30. The total value traded stands at ₹168.73 CR, and the delivery percentage for the day is 59.25%.
The stock is currently traded with a market lot size of 1. Dr Reddy's Laboratories. also offers a dividend yield of 0.58%.
Dr Reddy's Laboratories Share Price Chart
Dr Reddy's Laboratories. Share Key Metrics
Volume
12.23 L
Market Cap
115736.77 CR
LTQ@LTP
1@1386.60
ATP
1380.06
Var Margin
12.74 %
Circuit Range
1239.3-1514.7
Delivery %
59.25 %
Value
168.73 CR
ASM/GSM
No
Market Lot
1
Dr Reddy's Laboratories. Resistance and Support
Pivot 1382.8
Resistance
First Resistance
1393.2
Second Resistance
1409.4
Third Resistance
1419.8
Support
First Support
1366.6
Second Support
1356.2
Third Support
1340
Dr Reddy's Laboratories. Futures & Options
1386.6
9.6 (0.7%)
Dr Reddy's Laboratories. Option Chain
View Price, OI, Greeks & More...
23NOV26
1387.70
5.10 (0.37%)
29DEC26
1393.00
6.50 (0.47%)
25JAN27
1386.90
-0.40 (0.03%)
DRREDDY|23NOV26 CE 1380.00
24.30
0.6 (2.53%)
DRREDDY|23NOV26 PE 1390.00
22.55
-3.9 (-14.74%)
Dr Reddy's Laboratories. Shareholding Pattern
View More- 2016-17
- 2017-18
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Dr Reddy's Laboratories. Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-23 | Quarterly Results |
| 2026-07-22 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-01-21 | Quarterly Results |
| 2025-10-24 | Quarterly Results |
| 2025-07-23 | Quarterly Results |
| 2025-05-09 | Audited Results |
| 2025-01-23 | Quarterly Results |
| 2024-11-05 | Quarterly Results |
| 2024-07-27 | Quarterly Results & Stock Split |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-10 | 2026-07-10 | View More |
| Split Ratio | Split Date | |
|---|---|---|
| 5:1 | 2024-10-28 | View More |
Dr Reddy's Laboratories. News
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
DrReddys_ESOP_Allotment: 591270 shares under ADR Stock Option Scheme 2007.
Nov 04 2026 12:03:35
Dr Reddys Laboratories Ltd - 500124 - Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr Reddys confirmed the news regarding US FDA tentative approval for its twice-yearly injectable lenacapavir. The $40 generic HIV prevention shot aims to advance access across 120 poorer countries outside the US.
Nov 04 2026 11:45:54
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
The USFDA has classified the inspection outcome at Dr Reddys Srikakulam FTO-SEZ Process Unit-02 as 'Voluntary Action Indicated' (VAI). The inspection is now officially closed. This resolves the PAI and GMP inspections conducted earlier in July 2026.
Oct 28 2026 18:29:39
Dr Reddys Laboratories Ltd - 500124 - Board Meeting Outcome for Outcome Of Board Meeting
Dr Reddys Laboratories reported Q2 FY27 cons. revenue of ₹8,670.8 crores, down 1.5% YoY, and net profit of ₹925 crores, down 36% YoY. The decline was largely driven by lower North America sales. Additionally, Akhil Ravi was appointed as Head API and Services effective November 13, 2026.
Oct 23 2026 18:39:36
Dr Reddys Laboratories Ltd - 500124 - Copy Of Investor Presentation
Dr. Reddy's Laboratories issued its Q2 FY27 investor presentation, reporting revenue of Rs.8,671 crores and net profit of Rs.925 crores. The company highlighted double-digit base business growth, alongside key strategic partnerships with Takeda for a dengue vaccine and Gilead for lenacapavir.
Oct 23 2026 17:37:10
Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's Laboratories secured DCGI approval for Zytorvi in combination with cisplatin and paclitaxel for treating advanced esophageal squamous cell carcinoma. This marks the drug's second approved indication in India, expanding its immunotherapy reach.
Oct 21 2026 09:39:21
Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Dr. Reddy's Laboratories received a USFDA Form 483 with three observations after a pre-approval inspection at its Visakhapatnam FTO-9 facility. The inspection was conducted from October 8 to October 9, 2026.
Oct 14 2026 20:20:51
Dr Reddy's Laboratories. Management
| Name | Position |
|---|---|
| K Randhir Singh | Company Secretary, Compliance Officer and Head-CSR |
| K Satish Reddy | Chairman |
Dr Reddy's Laboratories. Similar Stocks
Torrent Pharmaceuticals Ltd.
4727.20
-33.80 (0.71%)
Laurus Labs Ltd.
2400.00
-29.00 (1.19%)
Lenskart Solutions Ltd.
727.45
4.35 (0.60%)
Apollo Hospitals Enterprise Ltd.
8515.00
-89.00 (1.03%)
Zydus Lifesciences Ltd.
1206.00
6.50 (0.54%)
Cipla Ltd.
1408.30
-11.60 (0.82%)
Mankind Pharma Ltd.
2638.60
-21.40 (0.80%)
Aurobindo Pharma Ltd.
1807.20
-20.30 (1.11%)
Lupin Ltd.
2015.00
-8.40 (0.42%)
Max Healthcare Institute Ltd.
946.30
18.00 (1.94%)
Dr Reddy's Laboratories. FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in DRREDDY
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC